Abstract: The present invention relates to engineered a cytolytic immune cell comprising: i) a releasable protein which comprises a polypeptide of interest (POI) and a first interaction domain; and ii) a retention protein which is retained within an intracellular compartment of the cell and comprises a second interaction domain which binds to the first protein interaction domain, wherein binding between the first protein interaction domain and second protein interaction domain is disrupted by the presence of an agent, such that in the absence of the agent, the first protein interaction domain and second protein interaction domain bind and result in retention of the POI within an intracellular compartment; whereas in the presence of the agent, the first protein interaction domain and second protein interaction do not bind and the POI is released from the intracellular compartment and expressed at the cell surface or secreted by the cell.

Abstract: The present disclosure relates to anti-TRBCl antigen binding domains characterized by the sequences of the variable chains. The CDRs sequences of the variable chains are: (VH CDR1) GYTFT, (VH CDR2) NPYNDDIQS, (VH CDR3) GAGY-NFDGAYRFFDF; and (VL CDR1) RSSQRLVHSNGNTYL, (VL CDR2) RVSNRFP, (VL CDR3) SQSTHVPYT. The claimed humanized antibodies derive from the murine JOVI antibody. Uses in cancer therapy.

Abstract: The present disclosure relates to anti-TRBC1 antigen binding domains characterized by the sequences of the variable chains. The CDRs sequences of the variable chains are: (VH CDR1) GYTFT, (VH CDR2) NPYNDDIQS, (VH CDR3) GAGY-NFDGAYRFFDF; and (VL CDR1) RSSQRLVHSNGNTYL, (VL CDR2) RVSNRFP, (VL CDR3) SQSTHVPYT. The claimed humanized antibodies derive from the murine JOVI antibody. Uses in cancer therapy.

Abstract: The present disclosure relates to anti-TRBC1 antigen binding domains characterized by the sequences of the variable chains. The CDRs sequences of the variable chains are: (VH CDR1) GYTFT, (VH CDR2) NPYNDDIQS, (VH CDR3) GAGYNFDGAYRFFDF; and (VL CDR1) RSSQRLVHSNGNTYL, (VL CDR2) RVSNRFP, (VL CDR3) SQSTHVPYT. The claimed humanized antibodies derive from the murine JOVI antibody. Uses in cancer therapy.

Abstract: The present disclosure relates to anti-TRBC1 antigen binding domains characterized by the sequences of the variable chains. The CDRs sequences of the variable chains are: (VH CDR1) GYTFT, (VH CDR2) NPYNDDIQS, (VH CDR3) GAGY-NFDGAYRFFDF; and (VL CDR1) RSSQRLVHSNGNTYL, (VL CDR2) RVSNRFP, (VL CDR3) SQSTHVPYT. The claimed humanized antibodies derive from the murine JOVI antibody. Uses in cancer therapy.

Abstract: The present invention relates to engineered a cytolytic immune cell comprising: i) a releasable protein which comprises a polypeptide of interest (POI) and a first interaction domain; and ii) a retention protein which is retained within an intracellular compartment of the cell and comprises a second interaction domain which binds to the first protein interaction domain, wherein binding between the first protein interaction domain and second protein interaction domain is disrupted by the presence of an agent, such that in the absence of the agent, the first protein interaction domain and second protein interaction domain bind and result in retention of the POI within an intracellular compartment; whereas in the presence of the agent, the first protein interaction domain and second protein interaction do not bind and the POI is released from the intracellular compartment and expressed at the cell surface or secreted by the cell.

Abstract: The present invention provides a chimeric receptor which binds a target antigen on a target cell, which comprises: a first antigen binding domain which binds a first epitope of the target antigen, a second antigen binding domain which binds a second epitope of the target antigen; a transmembrane domain; and an intracellular signalling domain.

Abstract: The present disclosure relates to anti-TRBC1 antigen binding domains characterized by the sequences of the variable chains. The CDRs sequences of the variable chains are: (VH CDR1) GYTFT, (VH CDR2) NPYNDDIQS, (VH CDR3) GAGYNFDGAYRFFDF; and (VL CDR1) RSSQRLVHSNGNTYL, (VL CDR2) RVSNRFP, (VL CDR3) SQSTHVPYT. The claimed humanized antibodies derive from the murine JOVI antibody. Uses in cancer therapy.

Abstract: The multi-purpose, ultra-broadband antenna structure is comprised of a radiating element, a conducting ground plate, a feed line, a grounded mini-tab section and a radio frequency input connector. The grounded mini-tab section represents a unique concept and is quite different from other techniques to provide broadband capability. The antenna structure does not use any dielectric substrate or bonding agent or discrete impedance matching circuit or tuning mechanism, thereby providing a low-cost, compact, low-profile and rugged antenna design capable of operating over ultra-wideband under severe operating environments. This antenna can operate under harsh mechanical and thermal environments with no degradation in reliability or performance or structural integrity. The antenna permits easy integration of frequency hopping and direct-sequence spread spectrum techniques to provide immunity against co-channel interference, multipath reflections, signal fading, and electronic jamming.

Abstract: The Satellite Communication System disclosed in the specification is a dynamic constellation (C) of satellites (S). The present invention is capable of offering continuous voice, data and video service to customers across the globe on the land, on the sea, or in the air. The preferred embodiment of the invention comprises a low Earth orbit satellite system that includes 40 spacecraft (S) traveling in each of 21 orbital planes at an altitude of 700 km (435 miles). This relatively large number of satellites employed by the preferred embodiment was selected to provide continuous coverage of the Earth's surface at a high minimum mask angle (1230a) of forty degrees. Each of the individual 840 spacecraft (S) functions as an independent sovereign switch of equal rank which knows the position of its neighbors, and independently handles traffic without ground control.

Abstract: Terrestrial antennas (10A, 10B, 10C and 10D) which are capable of transmitting and receiving radio signals directly to and from satellites in low Earth orbit are disclosed. The preferred embodiment of the invention employs circularly polarized, dual-frequency printed circuit antenna elements (136) measuring only a fraction of an inch in diameter. One embodiment (10A) includes an elevation array and an azimuth array which both reside on a trapezoidal, semi-conical housing that resembles a flattened pyramid. Both the top and the curved exterior of the pyramid support circular, slotted, printed circuit patches on their surfaces which bound individual radiating antenna elements (18). Since the entire antenna is only a few inches in diameter and is less than two inches high, it can be incorporated as an integral element of a telephone (T) or can be mounted at the end of a collapsible mast (CM).

Abstract: Terrestrial antennas (10A, 10B, 10C and 10D) which are capable of transmitting and receiving radio signals directly to and from satellites in low Earth orbit are disclosed. The preferred embodiment of the invention employs circularly polarized, dual-frequency printed circuit antenna elements (136) measuring only a fraction of an inch in diameter. One embodiment (10A) includes an elevation array and an azimuth array which both reside on a trapezoidal, semi-conical housing that resembles a flattened pyramid. Both the top and the curved exterior of the pyramid support circular, slotted, printed circuit patches on their surfaces which bound individual radiating antenna elements (18). Since the entire antenna is only a few inches in diameter and is less than two inches high, it can be incorporated as an integral element of a telephone (T) or can be mounted at the end of a collapsible mast (CM).